Special Summer Savings on Quell Devices – Ending Soon Shop Now
Sleep Review 08/31/2015

In RLS Patients, NeuroMetrix Reports Positive Pilot Data

Quell Wearable Pain Relief Technology

Wearable medical technology and point-of-care test developer NeuroMetrix Inc today announced preliminary results from a pilot study of its wearable pain relief technology in subjects with restless leg syndrome (RLS).

RLS, which is also known as Willis-Ekbom Disease, is a common sleep disorder characterized by a strong urge to move the legs at night. In addition to its direct impact on sleep, RLS may increase the risk of cardiovascular disease and is associated with an overall higher risk of mortality. One way to manage RLS is via various pharmacological agents, some of which worsen the symptoms over time.

The pilot study was an open-label, single-arm, flexible dosing, 4-week trial. The objective of the study was to determine if transcutaneous electrical nerve stimulation (TENS), when delivered using a wearable intensive nerve stimulation device (NeuroMetrix SENSUS), is an effective and safe treatment for RLS, and to explore its effect on sleep in subjects with RLS. The principal investigator was John W. Winkelman MD, PhD, chief of the Sleep Disorders Clinical Research Program, Departments of Psychiatry and Neurology at Massachusetts General Hospital (a Harvard Medical School teaching hospital).

A total of nine subjects were evaluated. Two-thirds of the subjects were responders to the therapy according to the Clinical Global Impression of improvement (CGI-I) scale. Overall RLS severity decreased by 32%, as assessed by the International Restless Leg Syndrome (IRLS) scale, which was statistically significant. Similarly, several sleep-related outcomes measures (MOS Sleep Scale) showed statistically significant (or a trend towards) improvement. A complete set of results and analyses will be published by Winkelman, who said in a release, “Pharmacologic treatments, though an important advance over the past 20 years for patients with RLS, leave much to be desired. Effective non-pharmacological treatments would be of great value, and these are encouraging preliminary results that must now be confirmed in a sham-controlled study.”

Read More

Any Questions?

We're here for you.

Get in touch with us
or call 800.204.6577

Try Quell for yourself

It's risk free with our 60 day money back guarantee